Topline results reported from Japanese phase II study of vadadustat in NDD-CKD Sep. 27, 2017 No Comments
Catalyst Biosciences' CB-2679d awarded FDA orphan drug status for hemophilia B Sep. 27, 2017 No Comments
FDA grants rare pediatric disease designation to Altemia for SCD in children Sep. 22, 2017 No Comments
EMA committee recommends approval of 10 mg rivaroxaban for extended prevention of VTE Sep. 19, 2017 No Comments
Catalyst Biosciences reports initial data from phase I/II study of CB-2679d in hemophilia B Sep. 7, 2017 No Comments
RSS